MA49521A - Nanoparticule, agent de contraste pour imagerie par résonance magnétique la contenant, et composé ligand - Google Patents

Nanoparticule, agent de contraste pour imagerie par résonance magnétique la contenant, et composé ligand

Info

Publication number
MA49521A
MA49521A MA049521A MA49521A MA49521A MA 49521 A MA49521 A MA 49521A MA 049521 A MA049521 A MA 049521A MA 49521 A MA49521 A MA 49521A MA 49521 A MA49521 A MA 49521A
Authority
MA
Morocco
Prior art keywords
nanoparticle
contrast
agent
magnetic resonance
resonance imaging
Prior art date
Application number
MA049521A
Other languages
English (en)
Inventor
Takuzo Aida
Ichio Aoki
Daigo Miyajima
Seunghyun Sim
Toshiaki Takeuchi
Original Assignee
National Institutes For Quantum And Radiological Science And Tech
Riken
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by National Institutes For Quantum And Radiological Science And Tech, Riken filed Critical National Institutes For Quantum And Radiological Science And Tech
Publication of MA49521A publication Critical patent/MA49521A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
    • A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
    • A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
    • A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
    • A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
    • A61K49/1827—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle
    • A61K49/1833—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with a small organic molecule
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y30/00—Nanotechnology for materials or surface science, e.g. nanocomposites
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C309/13—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing nitrogen atoms, not being part of nitro or nitroso groups, bound to the carbon skeleton
    • C07C309/14—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing nitrogen atoms, not being part of nitro or nitroso groups, bound to the carbon skeleton containing amino groups bound to the carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Nanotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Radiology & Medical Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Materials Engineering (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Physics & Mathematics (AREA)
  • Condensed Matter Physics & Semiconductors (AREA)
  • Composite Materials (AREA)
  • Physics & Mathematics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
MA049521A 2017-06-28 2018-06-27 Nanoparticule, agent de contraste pour imagerie par résonance magnétique la contenant, et composé ligand MA49521A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2017126755 2017-06-28

Publications (1)

Publication Number Publication Date
MA49521A true MA49521A (fr) 2020-05-06

Family

ID=64742350

Family Applications (1)

Application Number Title Priority Date Filing Date
MA049521A MA49521A (fr) 2017-06-28 2018-06-27 Nanoparticule, agent de contraste pour imagerie par résonance magnétique la contenant, et composé ligand

Country Status (19)

Country Link
US (1) US11389550B2 (fr)
EP (1) EP3646888A4 (fr)
JP (1) JP7107532B2 (fr)
KR (1) KR20200018579A (fr)
CN (1) CN110799219B (fr)
AU (1) AU2018292927B2 (fr)
BR (1) BR112019027478A2 (fr)
CA (1) CA3068215A1 (fr)
CO (1) CO2020000940A2 (fr)
IL (1) IL271622A (fr)
JO (1) JOP20190290A1 (fr)
MA (1) MA49521A (fr)
MY (1) MY201491A (fr)
PH (1) PH12019502882A1 (fr)
RU (1) RU2767430C2 (fr)
SG (1) SG11201912664WA (fr)
UA (1) UA125049C2 (fr)
WO (1) WO2019004297A1 (fr)
ZA (1) ZA202000265B (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3124753A1 (fr) 2018-12-27 2020-07-02 Astellas Pharma Inc. Procede de production de nanoparticules comprenant des particules metalliques contenant de l'oxyde de fer ayant au moins un ligand hydrophile coordonne a celui-ci
KR20210109574A (ko) * 2018-12-27 2021-09-06 아스테라스 세이야쿠 가부시키가이샤 나노 입자, 이를 함유하는 자기 공명 영상용 조영제 및 양쪽성 이온 리간드 화합물

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3123542A (en) 1960-10-13 1964-03-03 Electrolytic marking medium
US20100166664A1 (en) 2008-12-29 2010-07-01 General Electric Company Nanoparticle contrast agents for diagnostic imaging
US8574549B2 (en) 2008-12-29 2013-11-05 General Electric Company Nanoparticle contrast agents for diagnostic imaging
JP6063627B2 (ja) 2008-12-29 2017-01-18 ゼネラル・エレクトリック・カンパニイ 診断イメージング用のナノ粒子造影剤
US8728529B2 (en) 2008-12-29 2014-05-20 General Electric Company Nanoparticle contrast agents for diagnostic imaging
US8728440B2 (en) 2012-08-23 2014-05-20 General Electric Company Nanoparticulate compositions for diagnostic imaging
US9399075B2 (en) 2008-12-29 2016-07-26 General Electric Company Nanoparticle contrast agents for diagnostic imaging
US9205155B2 (en) 2009-10-30 2015-12-08 General Electric Company Treating water insoluble nanoparticles with hydrophilic alpha-hydroxyphosphonic acid conjugates, the so modified nanoparticles and their use as contrast agents
KR20130045647A (ko) * 2011-10-26 2013-05-06 한국기초과학지원연구원 양쪽성 이온으로 코팅된 자기공명영상 조영제
WO2013090601A2 (fr) * 2011-12-16 2013-06-20 Massachusetts Institute Of Technology Nanoparticules compactes pour des applications biologiques
US8821838B2 (en) 2012-08-23 2014-09-02 General Electric Company Nanoparticulate compositions for diagnostic imaging
CN104740654B (zh) 2013-12-30 2017-12-29 中国科学院化学研究所 磁性纳米颗粒磁共振造影剂和增强磁性纳米颗粒弛豫率的方法
HUE046306T2 (hu) 2014-01-07 2020-02-28 Colorobbia Italiana Spa Katekollal funkcionalizált mágneses nanorészecskék, elõállításuk és alkalmazásuk
JP6471227B2 (ja) * 2014-09-15 2019-02-13 マサチューセッツ インスティテュート オブ テクノロジー 磁気共鳴画像法用途のためのナノ粒子
JP6577250B2 (ja) * 2015-06-02 2019-09-18 国立大学法人 東京大学 複合半透膜
CN106390146A (zh) 2015-08-03 2017-02-15 天津大学 聚磺酸甜菜碱两性电解质修饰的磁性纳米粒子及其制备方法和应用

Also Published As

Publication number Publication date
CN110799219A (zh) 2020-02-14
RU2019143780A (ru) 2021-06-25
RU2767430C2 (ru) 2022-03-17
CA3068215A1 (fr) 2019-01-03
CO2020000940A2 (es) 2020-02-18
KR20200018579A (ko) 2020-02-19
JPWO2019004297A1 (ja) 2020-04-30
EP3646888A4 (fr) 2021-04-14
US11389550B2 (en) 2022-07-19
IL271622A (en) 2020-02-27
PH12019502882A1 (en) 2020-10-26
ZA202000265B (en) 2021-07-28
MY201491A (en) 2024-02-27
US20200330617A1 (en) 2020-10-22
BR112019027478A2 (pt) 2020-07-07
SG11201912664WA (en) 2020-01-30
CN110799219B (zh) 2023-01-06
AU2018292927A1 (en) 2020-02-06
JOP20190290A1 (ar) 2019-12-19
RU2019143780A3 (fr) 2021-08-27
UA125049C2 (uk) 2021-12-29
JP7107532B2 (ja) 2022-07-27
WO2019004297A1 (fr) 2019-01-03
EP3646888A1 (fr) 2020-05-06
AU2018292927B2 (en) 2021-11-25

Similar Documents

Publication Publication Date Title
IL284686A (en) Treatment of beta-thalassemia using ACTRII ligand traps
IL266847B (en) Cancer treatment methods that include tigit binding agents
IL264598A (en) Antibody-protein nanoparticle complexes adapted for cancer therapy
MA44145A (fr) Anticorps anti-cd20/anti-cd3 bispécifiques pour traiter la leucémie aiguë lymphoblastique
EP3582687C0 (fr) Système d'imagerie par particules magnétiques à ligne de champ nul et à configuration ouverte
MA51139A (fr) Dérivés de 1-(pipéridinocarbonylméthyl)-2-oxopipérazine pour le traitement du cancer
MA41453A (fr) Encapsulation d'agents actifs très puissants
MA52253A (fr) Formulation de poudre nasale pour le traitement de l'hypoglycémie
EP3325992A4 (fr) Imagerie par résonance magnétique quantitative du système vasculaire
MA49116A (fr) Compositions pharmaceutiques contenant de l'insuline
FR3032330B1 (fr) Systeme pour la collecte des liquides s'ecoulant sur le sol d'une enceinte pour l'elevage d'animaux
DK3241551T3 (da) Farmaceutisk sammensætning til behandling af kræft, indeholdende lactatmetalsalt
MA49521A (fr) Nanoparticule, agent de contraste pour imagerie par résonance magnétique la contenant, et composé ligand
FR3028140B1 (fr) Systeme pour la collecte des liquides s'ecoulant sur le sol d'une enceinte pour l'elevage d'animaux
MA47776A (fr) Polythérapies pour le traitement du cancer du sein
IL272571A (en) NR4A1 ligands, pharmaceutical compositions, and related methods of use
EP3491007A4 (fr) Ligands radiomarqués pour imagerie pet/spect ciblée et leurs procédés d'utilisation
IT201700105483A1 (it) Metodo per la diagnosi e la prognosi di patologie neurodegenerative e neuroinfiammatorie
DK3517642T3 (da) Nikkel-chrom-jern-baseret støbelegering
ZA202104733B (en) Nanoparticle, contrast agent for magnetic resonance imaging comprising same and zwitterionic ligand compound
EP2910547A4 (fr) Composé, tautomère et isomère géométrique de celui-ci, sel dudit composé, tautomère ou isomère géométrique, procédé de fabrication dudit composé, tautomère, isomère ou sel, ainsi qu'agent antimicrobien et médicament anti-infectieux
FR3010635B1 (fr) Compositions pharmaceutiques a base d'agent filmogene pour le traitement de l'hyposialie
FR3049441B1 (fr) Capsule multi-compartiments pour iontophorese
IL245861A0 (en) Use of substances to treat drug-resistant tumors
ITUA20163044A1 (it) Dispositivo magnetico per la cattura di impurita' ferrose nei carri trincia miscelatori di foraggi unifeed